-
Patent Agency Ranking
公开(公告)号：US20230032101A1
公开(公告)日：2023-02-02
申请号：US17772334
申请日：2020-10-23
Inventor： Wenhu DUAN , Meiyu GENG , Zhengsheng ZHAN , Zuoquan XIE , Kaiyan ZHAO , Yuting GUO , Xiyuan WANG , Yan ZHANG , Xiaoqian ZHOU , Jian DING
IPC: C07D409/04 , C07D405/04 , C07D333/22 , C07D407/04 , C07D495/04 , C07D417/04 , C07D471/04 , C07D409/14 , A61P35/00
Abstract: A five-membered heterocyclic oxocarboxylic acid compound and the medical use thereof are described. Specifically, provided are a compound as represented by formula (I) and a pharmaceutically acceptable salt, prodrug, hydrate, solvate or crystal form thereof, and also a method for preparing the compound, a pharmaceutical composition containing the compound, and the medical use thereof as a secretion regulator of type I interferon, especially as a STING agonist, and the preparation of a drug for preventing and/or treating diseases related to type I interferon.
-
公开(公告)号：US20230382871A1
公开(公告)日：2023-11-30
申请号：US18027759
申请日：2021-09-22
Inventor： Jian DING , Wenhu DUAN , Hua XIE , Meiyu GENG , Caixia WANG , Zhengsheng ZHAN , Na GAO , Yang ZHANG
IPC: C07D231/56 , A61P35/00 , C07K16/28
CPC classification number: C07D231/56 , A61P35/00 , C07K16/2818 , C07K16/2827 , A61K2039/505
Abstract: Provided is the use of a CSF1R kinase inhibitor compound or a pharmaceutically acceptable salt thereof in the preparation of drugs for treating diseases related to the CSF1R kinase signal transduction pathway or drugs for regulating immunization.
-
公开(公告)号：US20220324869A1
公开(公告)日：2022-10-13
申请号：US17640424
申请日：2020-09-03
Inventor： Wenhu DUAN , Meiyu GENG , Hefeng ZHANG , Jian DING , Jing AI , Xia PENG , Yinchun JI
IPC: C07D487/04 , A61P35/00 , C07D401/14 , C07D405/14 , C07F7/08
Abstract: A compound having Axl and c-Met kinase inhibitory activity, a preparation method therefor and an application thereof are provided. Specifically, provided herein are a compound having the structure represented by formula (I), a preparation method therefor and an application thereof in the preparation of a medication for the treatment and/or prevention of tumor-associated diseases and/or kinase-related diseases.
-
公开(公告)号：US20220389025A1
公开(公告)日：2022-12-08
申请号：US17761252
申请日：2020-09-21
Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences , China Pharmaceutical University
Inventor： Wenhu DUAN , Meiyu GENG , Huibin ZHANG , Zuoquan XIE , Jinpei ZHOU , Yifei YANG , Xiyuan WANG , Xiaojun YANG , Yan ZHANG , Zhaoxue HU , Jian DING
IPC: C07D491/048 , C07D519/00 , A61P35/00
Abstract: Provided are a heterocyclic amide compound of general formula (I), a pharmaceutically acceptable salt thereof and a preparation method therefor, and the use of the compound in the preparation of a drug for treating diseases related to the activity of STING, in the preparation of an immunologic adjuvant, and in the preparation of a drug for activating STING.
-
公开(公告)号：US20170066723A1
公开(公告)日：2017-03-09
申请号：US15120771
申请日：2015-02-15
Inventor： Wenhu DUAN , Jian DING , Yongcong LV , Hua XIE
IPC: C07D231/56 , C07D261/20 , C07D413/12 , C07D401/12 , C07D491/048 , C07D495/04
CPC classification number: C07D231/56 , C07D261/20 , C07D401/12 , C07D413/12 , C07D491/048 , C07D495/04
Abstract: The present invention relates to a naphthylamide compound of the structure as represented by formula (I), medicinal salts, prodrugs and hydrates or solvates thereof, and also relates to a method of preparing the compounds, pharmaceutical compositions comprising the compounds and the uses thereof as protein tyrosine kinase inhibitors, particularly as VEGFR-2 inhibitors, in preparing drugs for preventing and treating diseases related to abnormal angiogenesis.
Abstract translation: 本发明涉及由式（I）表示的结构的萘酰胺化合物，其药物盐，前药和水合物或溶剂化物，还涉及制备该化合物的方法，包含该化合物的药物组合物及其用途为 蛋白酪氨酸激酶抑制剂，特别是作为VEGFR-2抑制剂，在制备用于预防和治疗与异常血管生成有关的疾病的药物中。
-
-
-
-
Search Results
5
records
(took 0.021 seconds)
